Home Finance Johnson & Johnson Announces a Major Collaboration

Johnson & Johnson Announces a Major Collaboration

Sep 06, 2025 17:30 CST Updated Sep 08, 15:31

On September 5, Johnson & Johnson Medical Technologies and Rui Long Surgical announced a strategic partnership to jointly advanceSurgical TechniquesCommercialization Process in China。A product portfolio that leverages each other's complementary strengths,Including a series of innovative products from Johnson & Johnson Medical Technologies andRuilong Surgical SubsidiaryTheHai Shan Yi®Endoscopic surgeryRobot, willEffectively meet the needs of the broad massesMedical StaffIn terms of flexibility,Adaptability andClinical Needs in Terms of Accessibility,LetPatients in the country are expected to gain access to a broader range of minimally invasive surgical solutions.。

®Endoscopic Surgical Robot

Hai Mountain One®Endoscopic Surgical RobotApproved by the National Medical Products Administration in March 2025,It is the first split-type laparoscopic surgical robot in China, and alsoChinaThe first surgical robot approved for use in four major specialist indications (general surgery, thoracic surgery, gynecology, and urology) upon market launch.

Through this collaboration, Johnson & Johnson Medical Technologies will further enrich the selection of its product portfolio, providing more comprehensive solutions for surgeons, hospitals, and patients.

Zhou Mintao, President of Johnson & Johnson Medical Technology China, stated:"This collaboration fully integrates Johnson & Johnson's over three decades of local experience in the Chinese market with a globally advanced product portfolio. Surgical robots have ushered in a new era of minimally invasive surgery and are reshaping the landscape of surgical diagnosis and treatment. This strategic cooperation with Rui Long Surgical is an important milestone in integrating superior commercial resources and local innovation capabilities within the field of surgical robotics. We look forward to building the future of precision medicine through innovation and collaboration, better serving patients in China, and making new contributions towards a healthier future."